Dyax Corp. (NASDAQ:DYAX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications.

Recs

0
Player Avatar jwray01 (99.61) Submitted: 8/15/2012 2:24:13 AM : Underperform Start Price: $2.45 DYAX Score: -10.86

stock spam

Featured Broker Partners


Advertisement